Napabucasin
- Generic Name
- Napabucasin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H8O4
- CAS Number
- 83280-65-3
- Unique Ingredient Identifier
- Z1HHM49K7O
- Background
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- Conditions
- Oncology
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04299880
- Locations
- 🇯🇵
Kyorin University Hospital, Tokyo, Japan
🇺🇸Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 90
- Registration Number
- NCT03647839
- Locations
- 🇦🇺
Eastern Health, Box Hill, Victoria, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Ballarat Health Service, Ballarat, Victoria, Australia
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03525405
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Previously Treated Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- 1Globe Health Institute LLC
- Target Recruit Count
- 668
- Registration Number
- NCT03522649
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
- Conditions
- Drug-drug Interactions
- Interventions
- Drug: cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03411122
- Locations
- 🇺🇸
Accel Research Sites, DeLand, Florida, United States
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1134
- Registration Number
- NCT02993731
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Montefiore Cancer Center, Bronx, New York, United States
Special Combination of BBI608 and Pembrolizumab
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Takayuki Yoshino
- Target Recruit Count
- 55
- Registration Number
- NCT02851004
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02826161
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1253
- Registration Number
- NCT02753127
- Locations
- 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Dana Farber, Boston, Massachusetts, United States
🇨🇦University of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT02641873
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.